Pancreatic Cancer Research

ResearcherAmsterdam University Medical CentersNo recent work listed

Kun Shi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3026-9567; OpenAlex author ID A5101619528. Sources: OpenAlex.

Their work

Papers
6 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: 1 paper

Papers 6

  1. PAR1 signaling on tumor cells limits tumor growth by maintaining a mesenchymal phenotype in pancreatic cancer. First author DOI 10.18632/oncotarget.25880↗
  2. Dabigatran potentiates gemcitabine-induced growth inhibition of pancreatic cancer in mice. Co-author DOI 10.2119/molmed.2016.00214↗
  3. Authors' reply-Re: Shi et al. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer mod… Co-author DOI 10.1002/path.4499↗
  4. Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. First author DOI 10.1002/ijc.28726↗
  5. Protease-activated receptor 2 suppresses lymphangiogenesis and subsequent lymph node metastasis in a murine pancreatic cancer model. Co-author DOI 10.1002/path.4411↗
  6. Protease-activated receptor-2 induces migration of pancreatic cancer cells in an extracellular ATP-dependent manner. Co-author DOI 10.1111/jth.12361↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. C. Arnold Spek · 6 shared papers, 2013–2018 · strength 0.43
  2. Dick J. Richel · 4 shared papers, 2013–2017 · strength 0.22
  3. Karla C. S. Queiroz · 3 shared papers, 2013–2014 · strength 0.14
  4. Cansu Tekin · 1 shared paper, 2018 · strength 0.10
  5. Maarten F. Bijlsma · 1 shared paper, 2018 · strength 0.10
  6. Helene Damhofer · 1 shared paper, 2017 · strength 0.08
  7. Johanna W. Wilmink · 1 shared paper, 2014 · strength 0.04
  8. JanWillem Duitman · 1 shared paper, 2014 · strength 0.04

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.